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Abstract
Purpose: To evaluate a panel of pretreatment clinical and laboratory parameters in metastatic melanoma (MM)
in order to verify their impact on response and survival in a single prospective multi-institutional phase III study
comparing out-patient chemotherapy (CT) vs bioCT.
Methods: A total of 176 patients were randomised to receive CT (cisplatin, dacarbazine, optional carmustine)
o r  b i o C T  ( t h e  s a m e  C T  f o l l o w e d  b y  subcutaneous IL-2 plus intramuscular α-IFN-2b). Pretreatment total
leucocytes, lymphocytes, eosinophyls, C-reactive protein (CRP), lactate dehydrogenase (LDH),
erytrosedimentation rate (ESR), and fibrinogen were analyzed. Some clinical parameters (performance status, age,
sex, and disease site) were also considered. As we found a positive trend for bio-CT with no statistical significance
in OR (25.3% vs 20.2%) and OS (11 Mo vs 9.5 Mo), all analyses are stratified by treatment arm.
Results: In univariate analysis, higher value of lymphocytes percentage (P < .0001), lower value of total leucocytes
(P=.005), CRP (P=.003), LHD (P < .0001), ESR (P < .027), fibrinogen (P < .0001), and no liver disease were strongly
related to a better survival. In a multivariate analysis, using the Cox proportional hazards model, only fibrinogen
(P=.004), LDH (P=.009) and liver disease (P=.04) were found to have an independent role on clinical outcome in
metastatic melanoma patients.
Conclusion: Liver disease and higher LDH and fibrinogen levels had an important impact on survival in MM
patients. In particular, fibrinogen has been recently reconsidered both for its determinant role in the host
hemostatic system, and for its capability to provide protection against NK and LAK-cell-induced lysis. These
observations could have some important implications for therapeutic approaches, in particular when
immunological strategies are used.
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Introduction
The incidence of melanoma has increased more rapidly
over the last half century than that of all other forms of
cancer, except for lung cancer in female smokers. Earlier
diagnosis of primary disease has resulted in an increased
frequency of surgical cure with a 5 years survival rate of
80–100%, but in patients in which melanoma recurs, life
expectancy at 3 years is less than 10%, with a median sur-
vival of about 7 months [1,2].
The efficacy of adding immunotherapy to chemothera-
peutic regimens in metastatic melanoma (MM) is ques-
tionable. The first few published phase III trials seem to
indicate a greater efficacy of combined chemoimmuno-
therapy as far as response rates are concerned, but toxicity
and quality of life seem to worsen and overall survival rate
is not always higher [3,4].
Several studies have attempted to identify factors that
have an important impact on response and survival in
metastatic melanoma (MM) patients. All these studies
resulted in opportunities for stratification of patients for
clinical trials using some clinical and laboratory parame-
ters. In fact, the current American Joint Committee on
Cancer (AJCC) staging system distinguishes in M category
three different prognostic groups according to metastatic
sites and serum levels of lactate dehydrogenase [5].
Among clinical parameters, the number and the pattern of
metastatic disease were found to be two statistically signif-
icant prognostic factors that strongly correlated with sur-
vival [6-9]. For instance patients with liver involvement
have a very poor prognosis similar to those with central
nervous system disease [10]. Soft tissue and/or single vis-
ceral organ metastases were independent positive predic-
tors for survival [9,11]. Also poor performance status and
the presence of symptoms (reduced appetite, fever, nau-
sea/vomiting), and sex (male patients) were associated
with a poorer survival [6-8,10,11]. On the contrary,
period of enrollment (enrollment late in the decade) and
prior immunotherapy were associated with an improved
prognosis [9,11].
In patients treated with interleukin-2-based immuno-
therapy, visceral metastases were again correlated with a
poorer clinical response [12]. In addition, in patients
treated with high-dose intravenous bolus IL-2, the pres-
ence of only subcutaneous and/or cutaneous metastases
was associated to a higher response rate (53.6 %) with
respect to other sites of disease (12.4%). Moreover,
responding patients developed long-term immunologic
side effects such as abnormal thyroid function tests and
vitiligo [13].
A series of laboratory parameters has been also correlated
with response and survival in MM patients. Pre-treatment
high level of LDH and low levels of albumin showed the
capability of predicting survival behaviour in a significant
and adequate way. [7-9,11]. Also abnormal baseline val-
ues of alkaline phosphatase, and platelets were found
prognostic for a poorer survival [9]. C-reactive protein
(CRP) together with clinically defined group (patients
with superficial or visceral metastases) were found to be
indipendent predictors on multifactorial analysis in
patients treated with IL-2 containing therapy. Thus,
patients with high levels of CRP and/or visceral organ
involvement could be unlikely to respond to IL-2 therapy
[12].
Most data regarding pretreatment values of total lym-
phocytes and lymphocyte subsets in cancer patients have
been recently published, but their real impact on clinical
outcome and prognosis is still unclear [14]. Among
patients treated with high-dose intravenous bolus IL-2,
responding patients developed a higher maximum lym-
phocytes count immediately after therapy with respect to
non-responding patients but baseline lymphocytes seem
to have no impact on survival [13].
Finally, the role of fibrinogen in the metastatic potential
of tumor cells has been recently reconsidered both for its
determinant role in the host hemostatic system, and for its
capability to providing protection against NK and LAK-
cell-induced lysis [15-17].
In our single prospective multi-institutional phase III
study comparing out-patient chemotherapy (CT) versus
bioCT, we analyzed a panel of pretreatment laboratory
and clinical factors to verify their impact on response and
survival. Among the laboratory parameters we considered:
total leucocytes, lymphocytes, eosinophyls, C-reactive
protein (CRP), lactate dehydrogenase (LDH), erytrosedi-
mentation rate (ESR), and fibrinogen. Finally, we evalu-
ated also some clinical parameters: performance status
(PS), age, sex, and disease site.
Patients and Methods
Patients and treatment
We carried out a multicentric randomized study to com-
pare the standard polychemotherapeutic scheme
including DTIC and CDDP with a chemo-immunothera-
peutic scheme adding low dose of IL-2 and α-IFN subcu-
taneously, as immunomodulants. The participating
centres had the choice of adding carmustine (BCNU) to
the chemotherapeutic schedule for all their patients, obvi-
ously in both arms and for the whole duration of the
treatment.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/13
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Patients with histologically proven advanced melanoma
were enrolled in the study between March 1st 1997 and
December 31st 1999. Patient characteristics are listed in
Table 1. Detailed analyses of these clinical characteristics
have been reported previously [18].
Before each cycle clinical examination, determination of
complete blood count and biochemical analysis were per-
formed; after every two cycles during therapy and every
three months thereafter until progression, the patients
received a chest CT-scan or x-ray, liver CT scan or ultra-
sonography examination.
All patients gave their informed written consent to receive
treatment and the study was examined and approved by
the Ethical committees of every Local Health and Social
Service of each center included in the study in accordance
with the ethical standards laid down in the 1964 Declara-
tion of Helsinki.
All patients were randomized to receive treatment with
either chemotherapy (CT) or chemoimmunotherapy
(bioCT). The treatment scheme used is the following: on
day 1 all patients received 75 mg/m2 CDDP i.v. with the
usual hydrating scheme, 800 mg/m2 DTIC i.v. and option-
ally 100 mg/m2 BCNU i.v.. The patients who were allo-
cated in the bioCT arm received exactly the same regimen
as the CT arm, with the addition of IL-2 and α-IFN as
immunomodulants. The dose of IL-2 used was 4,500,000
IU given subcutaneously from day 3 to 5 and 8 to 12. α-
IFN-2b was given intramuscularly at the dose of
3,000,000 U on days 3, 5 and then 3 times a week. The
treatment was repeated every 21 days for six cycles or until
progression or severe toxicity. After the sixth cycle, the
bioCT arm patients continued to receive IL-2 and α-IFN
alone up to the twelfth month or until progression or
severe toxicity. Response evaluations and toxicity were
assessed according to WHO criteria as previously reported
[18].
Clinical and laboratory parameters
All patients were characterized according to some pre-
treatment clinical and laboratory parameters. Basal clini-
cal evaluations included performance status, age, sex, and
site of disease (liver versus no liver disease).
Finally a panel of laboratory parameters were also evalu-
ated before starting treatment and subsequently before
each treatment cycle. Data showed in this paper refer to
baseline evaluation only. Pre-treatment bio-humoral
parameters included total leukocytes (normal range up to
8500 cells/mm3), eosinophils (normal range up to 4% of
the total WBC) and lymphocytes (normal range 20%-40%
of the total WBC), CRP (normal range up to 1.5 mg/dl),
LDH (normal range, up to 460 U/L), erytrosedimentation
rate (ESR) (normal range up to 20 mm), and fibrinogen
Table 1: Patient Characteristics
CT BioCT
No. % No. %
No. patients 89 87
Sex
Male 57 64.0 48 55.2
Female 32 36.0 39 44.8
Age
Median 59 56
Range 26–76 25–77
Performance status (ECOG)
0 6 06 7 . 45 96 7 . 8
1 2 32 5 . 82 42 7 . 6
26 6 . 7 4 4 . 6
Site of primary melanoma
Head and neck 16 18.0 16 18.4
Body 35 39.3 36 41.4
Arms 34 38.2 34 39.1
Not referred 4 4.5 1 1.1
Sites of disease
Liver +/- others 30 33.7 32 36.8
Viscera +/- others 29 32.6 31 35.6
Bone + soft tissue and lymph nodes 4 4.5 2 2.3
Soft tissue and lymph nodes 26 29.2 22 25.3Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/13
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(normal range, up to 450 mg/dl). CRP was assayed by a
rate immunonephelometric technique on a protein sys-
tem analyser; for fibrinogen a quantitative assay standard-
ized photo-optical method was used; finally LDH
determination was performed using a UV-assay standard-
ized method.
Assessment of Clinical Response
Tumor sites were objectively evaluated by physical exami-
nation and radiologic tests after every two cycles of ther-
apy and than every three months.
Standard definitions of complete and partial objective
response were used, as previously reported (18). Survival
was defined as the time interval between randomization
and death of the patient for any cause or the last follow-
up. Time to progression (TTP) was defined as the time
interval between the date of randomization and the date
of disease progression or last follow-up.
Statistical analysis
The overall survival (OS), objective response (OR), TTP,
the toxicity profile, and quality of life (QoL) of patients
were evaluated in the eligible "intention to treat" (ITT)
population. Sample size was determined a priori in agree-
ment to the primary end point of the randomised study.
OS and TTP curves for the two arms were estimated by the
Kaplan and Meier method and then compared using the
Logrank test. As regards the response analysis, 95% confi-
dence interval (95%CI) of response rate was calculated,
and comparison between groups was assessed using
Fisher's exact test.
As we only found a positive trend for bio-CT pts vs CT
with no statistical significance in OR and OS, all analyses
regarding the parameters considered are stratified by treat-
ment arm. Univariate and multivariate analyses were per-
formed. In multivariate analyses the Cox proportional
hazards model was used to study the effects of different
variables on survival. This model was carried out on 129
patients who had available all pre-treatment variables
considered. Statistical significance was defined at P less
than .05 for univariate and multivariate analyses.
Since patients with liver involvement have a very poor
prognosis and in order to avoid a bias due to liver disease
impact on the laboratory parameters evaluated in the
study, we also considered this variable (liver disease yes or
not). As the explorative intent of this analysis, no P values
were adjusted for the multiplicity of the performed tests.
All P values were based on two-sided testing and statistical
analyses were carried out with SAS Statistical software
(SAS/STAT User's Guide, version 6, SAS Institute, Cary
NC, 1990).
Results
Survival and Response to treatment
A total of 178 patients were enrolled from 27 Italian cen-
tres; two of these patients were excluded from the study
because they were not eligible and 176 patients were eval-
uable for the efficacy analysis.
Median follow-up was 18 and 16 months for the CT and
bioCT groups respectively. Most relevant clinical results
included a median survival time of 1.5 months longer for
bioCT treated patients than for the CT group (11 vs 9.5
months), although no statistically significant difference
was found between the two treatment arms (HR = 0.888,
logrank = 0.442, p = 0.506). TTP was quite similar for the
two arms with a median TTP of 3.6 months for the bioCT
group and 3 months for CT treated patients (HR = 0.791,
logrank = 2.216, p = 0.137); finally the response rate was
25.3% and 20.2 respectively.
Table 2: Univariate Survival Analysis According To Clinical Characteristics
Clinical Variable No. Of patients Median Survival, Months (CI) Odds Ratio Log-Rank P
Liver Disease
Yes 114 12 (9.7–14.6) 2.4 (1.64–3.53)
No 62 6.3 (4.8–8.6) 0.0001
PS
0 119 1.6 (9.2–14.4) 1.85 (1.27–2.67) 0.001
1–2 57 6.9 (4.7–10.1)
Age
<60 years 99 9.2 (7.3–12.7) 0.97 (0.7–1.4) 0.85
≥ 60 years 77 10.7 (8.2–13.2)
Sex
Male 105 9.3 (7.8–11) 0.78 (0.54–1.12) 0.178
Female 71 12 (7.9–14.6)Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/13
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Clinical parameters
Among clinical parameters considered (age, sex, PS, pres-
ence or not of liver disease), only PS and liver disease were
found to have an important impact on patient survival
(Table 2). Patients with PS 0 had a median OS of 11.6
months compared with patients with PS 1–2 who had a
median OS of 6.9 months (P=.001). The presence of liver
disease had a stronger impact on patient survival with a
median OS of 12 months for patients without liver disease
with respect to 6.3 months in patients with liver disease (P
< .0001) (Figure 1).
The patient age and sex did not influence both the overall
response and survival.
Laboratory parameters
Regarding laboratory parameters, in univariate analysis,
pretreatment higher value of lymphocytes (P=.004 for
Kaplan-Meier survival curves according to PS (A) and presence or not of liver disease (B) Figure 1
Kaplan-Meier survival curves according to PS (A) and presence or not of liver disease (B).
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absolute lymphocyte count, and P < .0001 for the percent-
age count), lower value of CRP (P=.003), LDH (P <
.0001), ESR (P=.02), fibrinogen (P < .0001) and WBC
(P=.005) were related to a better survival (Table 3) (Figure
2). On the contrary, none of these factors was found to
correlate with response. A multivariate analysis, using the
Cox proportional hazards model, was carried out on 129
patients; in order to avoid a bias due to liver disease, we
also considered this variable (liver disease yes/no). From
an initial model, using a backward selection procedure, a
final parsimonious model was obtained. Only fibrinogen
(P=.0001), LDH (p=.009) and liver disease (P=.04) were
found to have independent impact on survival (Table 4).
Discussion
Commonly used treatment options for MM patients have
included chemotherapy alone or combined to immuno-
therapy. Unfortunately, these treatments are effective in
only a minority of patients. Indeed, the prognosis for
patients with metastatic melanoma still seems to be more
influenced by disease caracteristics than any particular
therapy.
Metanalyses carried out recently have demonstrated that
the association of chemotherapy with immunotherapy
including IL-2 and/or α-IFN, offers the highest response
percentage and long-term survival rates in MM patients
[19-21]. In our trial we only found a positive trend for bio-
CT pts versus CT with no statistical significance in OR
(25.3% vs 20.2%), TTP (3.6 vs. 3.0 months) and OS (11
vs 9.5 months).
Of interest is that some simple laboratory parameters such
as LDH, Fibrinogen, CRP, albumin are able to predict sur-
vival behaviour, supplanting more complex or subjective
factors, including sites of disease and patient PS [7,11].
Our analysis of potential prognostic factors confirmed the
importance of some laboratory known unfavourable
parameters (high LDH, ESR, CRP) and some clinical
aspects (poor basal PS and the presence of liver disease).
On the contrary, none of these factors was found corre-
lated to response. Two interesting new aspects which
emerged noticeably from this trial were the prognostic
value of the basal number of lymphocytes and the fibrin-
ogen level, which seem to be discriminating factors
between a good or bad survival prognosis.
Table 3: Univariate Survival Analysis According To Laboratory Parameters
Laboratory Parameters No. Of patients Median Survival, Months (CI) Odds Ratio Log-Rank P
White Blood Count
Normal 137 12 (8.7–13.2) 1.8 (1.18–2.8) 0.0057
High 37 6 (4–10.5)
Lymphocytes
Normal 100 12 (9.5–14.8) 1.67 (1.16–2.4) 0.0049
Low 72 7.8 (6.5–10.1)
Lymphocytes (%)
Normal 118 9.1 (9.7–14.7) 2.26 (1.5–3.3) 0.0001
Low 54 5.4 (4.4–7.9)
Eosinofili
Normal 171 10 (8.2–11.9) 1.82 (0.66–5.03) 0.23
High 5 4.3 (3–15.2)
Eosinofili (%)
Normal 126 9.2 (7.8–11.6) 0.77 (0.45–1.3) 0.32
High 25 13.2 (9.5–15.4)
LDH
Normal 121 12.4 (10.5–14.6) 2.77 (1.91–4.02) 0.0001
High 55 5.4 (4.2–7)
CRP
Normal 84 10.7 (8.5–14.7) 1.80 (1.2–2.67) 0.0031
High 62 7.4 (5.1–10.4)
ESR
Normal 70 13.2 (9.5–15.5) 1.57 (1.06–2.31) 0.022
High 83 8.5 (7–10.7)
Fibrinogen
Normal 107 11.8 (9.2–14.3) 2.37 (1.58–3.54) 0.0001
High 42 5.4 (4.7–8.3)Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/13
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Kaplan-Meier survival curves according to White Blood Count (A), Lymphocytes percentage (B) Figure 2
Kaplan-Meier survival curves according to White Blood Count (A), Lymphocytes percentage (B).
Table 4: Multivariate Survival Analysis According To Clinical and Laboratory Parameters.
Variable Hazard Ratio IC 95% Hazard ratio P
Liver Disease (yes vs no) 1.68 1.025–2.75 0.04
LDH (high vs normal) 1.89 1.17–3.06 0.009
Fibrinogen (high vs normal) 1.99 1.24–3.19 0.004
Evaluated 129 pts (parameters considered: PS, liver disease, lymphocytes, LDH, ESR, PCR, Fibrinogen and WBC)
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CRP is an acute-phase protein produced in the liver in
response to cyokines such as IL-6. In vivo, CRP seems
mainly to reflect IL-6 secretion [22] as supported by high
correlation demonstrated between serum CRP and the IL-
6 concentrations in melanoma patients [12]. Discord-
ances observed in some studies between CRP and IL-6
concentration may be explained by differences in kinetics
of secretion, since the increase of IL-6 is sometimes tran-
sient and occurs before CRP production. Also the action of
other cytokines could explain the discordance of CRP/IL-
6 levels [23,24]. Other Authors have also shown that ele-
vated pretreatment values of a specific inflammatory
Kaplan-Meier survival curves according to LDH (C), CRP (D) Figure 3
Kaplan-Meier survival curves according to LDH (C), CRP (D).
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markers, such as CRP and erythrosedimentation rate are
frequent in advanced cancer patients with poor prognostic
characteristics, such as cachexia [25]. Moreover, pretreat-
ment high levels of CRP predicts lack of IL-2 activity on
tumour objective response and its efficacy on overall sur-
vival in metastatic cancer patients [26]. However, these
findings have not been confirmed by others [13,27].
The impact of pretreatment values of total lymphocytes
and lymphocyte subsets in cancer patients remains ques-
tionable yet [14]. Lynphocytopenia [28] and/or a lower
lynphocyte percentage [29,30] seem to be independent
predictive factors for short survival in cancer patients,
whereas a higher lymphocyte number is related to longer
survival in patients with different neoplasms including
Kaplan-Meier survival curves according to ESR (E), Fibrinogen (F) Figure 4
Kaplan-Meier survival curves according to ESR (E), Fibrinogen (F).
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lung cancer [28], colorectal cancer [31], gastric cancer
[32].
In stage I-III melanoma patients, lower levels of total lym-
phocytes and of T-lymphocyte subset have been shown to
have a negative prognostic value when compared to
patients with normal values both in term of disease free
survival and overall survival [33]. As known, lymphocytes
play a fundamental role in mediating tumor cell destruc-
tion [34] and the rebound lymphocytosis represents the
typical biomarker of immune activation to IL-2 immuno-
therapy [35]. In fact, a higher lymphocyte rebound has
been observed after IL-2 therapy in responding patients
with metastatic renal cell cancer [36,37] and metastatic
melanoma [13]. In cancer patients receiving immuno-
therapy, the relative amount of CD4+, CD8+, and natural
killer cells have been found to correlate with a better sur-
vival [14]. Moreover, it has been recently advanced that
one of the underlying mechanisms responsible for the
compromised host immune response, could in part be
explained by a low production of endogenous IL-2 caused
by a decreased number and/or functionality of lym-
phocytes [37,38].
Recently, fibrinogen has been reconsidered as an impor-
tant determinant of the metastatic potential of tumor cells
[17]. A specific association between human cancer and
the hemostatic system has been recognized for more time.
Many significant hemostatic abnormalities have been
described in cancer patients including disseminated
intravascular coagulation, hemorrhagic events, and
migratory thrombophlebitis [39]. Many tumor cells pos-
sess strong procoagulant activities that promote the local
activation of the coagulation cascade resulting in both the
formation of tumor stroma and the promotion of hema-
togenous metastases. Fibrin matrices also promote neo-
vascularization. Moreover, fibrin degradation products
have also been shown to display powerful chemotactic,
immune-modulatory, as well as angiogenic properties.
Finally, the formation of platelet-fibrin-tumor aggregates
may be causally related to endothelial adhesion and met-
astatic potential. The generation of viable mouse lines
with selected deficits in key hemostatic factors has pro-
vided the opportunity to directly examine the role of
fibrinogen in tumor progression and spread. Using fibrin-
ogen-deficient and plasminogen-deficient transgenic mice
and transplantable murine tumor cell lines, it has been
demonstrated that fibrinogen deficiency strongly dimin-
ished the metastatic capability of tumor cells with a signif-
icant reduction in the number of surface pulmonary
metastases, although fibrinogen deficiency did not reduce
the growth rate of transplanted tumor cells [17]. This indi-
cates that initial establishment of metastatic foci, but not
tumor growth itself, was impaired in fibrinogen-deficient
mice.
Moreover, many detailed experimental in vitro studies
have demonstrated that melanoma cells with a highly
metastatic potential are able to utilize the host hemostatic
system for protection against the host immune system
using a covalent attachment to fibrinogen, either directly
or after its conversion into fibrin [16]. Interestingly, cyto-
toxicity experiments showed that the fibrinogen coating
on melanoma cells provided protection against LAK-cell-
induced lysis and that brief trypsinization restored the
susceptibility of the cells to lysis, due to removal of the
fibrinogen coating [15,16].
Lee et al [40] studied the role of fibrinogen covalently
associated with cell membrane in blood-borne lung
tumor colony formation of murine mammary carcinoma
cells in mice. Interestingly, in mice with hyperfibrinogen-
emia, induced by prednisolone administration or fibrino-
gen infusion of syngeneic mice, the coagulation time was
significantly accelerated and the number of lung tumor
colonies significantly increased. On the contrary, low
fibrinogen levels induced by rabbit antisyngenic mouse
fibrinogen immunoglobulins or heparin infusion, mark-
edly delayed coagulation time and reduced the numbers
of blood-borne lung tumor colonies of the tumor cells.
Also these Authors reported that the fibrinogen coating on
tumor cells provides protection against LAK-cell-induced
lysis. These observations could have potential implica-
tions for tumor metastasis studies and therapeutic
approaches, in particular when immunologic strategies
are used.
In conclusion, patient prognostic subgroups and the dif-
ferent treatments they should receive could be better iden-
tified on the basis of proven predictive factors. This
prospect might change if or when innovative therapeutic
strategies and different therapeutic options are available.
In summary, the current study represents one of the larg-
est single experience regarding prognostic factors in MM
patients. Our findings carried out in 176 consecutive MM
patients homogeneously treated in a single trial with
chemo or bio-chemotherapy, confirm that some labora-
tory and clinical factors are strongly related to survival in
MM patients, and they introduce a new simple laboratory
parameter, the fibrinogen, that could be utilized to better
identify patients with different prognosis.
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